Art. -Nr.: HY-N0035

Arctigenin

(Synonyms: (-)-Arctigenin)

17 Cited Publications

Kundenbewertung

Based on 17 publication(s) in Google Scholar

Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.63%
CAS. Nr.: 7770-78-7
Formel: C₂₁H₂₄O₆
Molecular Weight:372.41

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months

Arctigenin Chemical Structure

CAS. Nr.: 7770-78-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (17)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle MMP Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>50 μM Compound: ATG	Cytotoxicity against human A549 cells after 4 days under normal conditions by MTT assay Cytotoxicity against human A549 cells after 4 days under normal conditions by MTT assay	[PMID: 25571795]
A549	IC₅₀	6.57 μM Compound: ATG	Cytotoxicity against human A549 cells after 4 days under glucose-starved conditions by MTT assay Cytotoxicity against human A549 cells after 4 days under glucose-starved conditions by MTT assay	[PMID: 25571795]
A549	IC₅₀	0.8 μg/mL Compound: 9	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
H9	EC₅₀	0.42 μM Compound: 27	Antiviral activity against HIV1 infected in human H9 cells assessed inhibition of viral replication Antiviral activity against HIV1 infected in human H9 cells assessed inhibition of viral replication	[PMID: 9834179]
HeLa	EC₅₀	>100 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay	[PMID: 28754364]
HeLa	IC₅₀	572.7 μM Compound: Arctigenin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 30237124]
HepG2	IC₅₀	2.8 μg/mL Compound: 9	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
HL-60	EC₅₀	12 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay	[PMID: 28754364]
HL-60	IC₅₀	13 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as reduction in cell viability Cytotoxicity against human HL60 cells assessed as reduction in cell viability	[PMID: 32359854]
MDA-MB-231	IC₅₀	1.1 μg/mL Compound: 9	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
MRC5	CC₅₀	76 μM Compound: 7	Cytotoxicity against MRC5 cells Cytotoxicity against MRC5 cells	[PMID: 17239594]
MRC5	IC₅₀	2.1 μM Compound: 7	Antiviral activity against HCMV in MRC5 cells by plaque reduction assay Antiviral activity against HCMV in MRC5 cells by plaque reduction assay	[PMID: 17239594]
PANC-1	IC₅₀	2.2 μM Compound: Arctigenin	Growth inhibition of human PANC1 cells in nutrient-deprived medium incubated for 24 hrs by MTT assay Growth inhibition of human PANC1 cells in nutrient-deprived medium incubated for 24 hrs by MTT assay	[PMID: 30878830]
RAW264.7	IC₅₀	10 nM Compound: K00231, Arctigenin	Inhibition of LPS induced iNOS induced expression in mouse Raw264.7cells Inhibition of LPS induced iNOS induced expression in mouse Raw264.7cells	[PMID: 18077363]
RAW264.7	IC₅₀	0.26 mM Compound: 10	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs	[PMID: 18986199]
RAW264.7	IC₅₀	0.26 μM/mL Compound: 10	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs	[PMID: 18986199]
Sf9	IC₅₀	6.7 μM Compound: 1	Cytotoxicity against Spodoptera frugiperda Sf9 cells assessed as reduction in cell viability Cytotoxicity against Spodoptera frugiperda Sf9 cells assessed as reduction in cell viability	[PMID: 32359854]

In Vitro

Arctigenin (0.01-1 μg/mL; 0.5-24 h) shows preferential cytotoxicity against the PANC-1 cell line under nutrient-deprived conditions in a concentration- and time-dependent manner^[1].
Arctigenin (0.01-1 μg/mL; 0.5-24 h) inhibits the survival of various cancer cell lines (ASPC-1, BXPC-3, Alexander, and PSN-1 cells) under nutrient-deprived conditions^[1].
Arctigenin (0.1-1 μg/mL; 24 h) completely inhibits Akt phosphorylation stimulated by glucose deprivation in PANC-1 cells^[1].
Arctigenin (5-25 μM) shows potent in vitro antiviral activities (IC₅₀=2.9 μM) against influenza A virus^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Arctigenin (250 μg/mL; 0.2 mL; i.p. 6 times a week for 9 weeks) suppress the PANC-1 tumor growth in nude mice^[1].
Arctigenin (10 mg/kg; i.p. daily for 30 days) relieves experimental autoimmune encephalomyelitis (EAE) symptoms of mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female SPF/VAF BALB/cAn Ncrj-nu/nu mice were injected with PANC-1 cells^[1]
Dosage:

250 μg/mL, 0.2 mL
Administration:

I.p. 6 times a week for 9 weeks
Result:

Reduced the tumor weight and volume.
No significant body weight loss was recognized.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 7770-78-7
Appearance Solid
Molecular Weight 372.41
Formel C₂₁H₂₄O₆
Color White to off-white
SMILES

O=C1OC[C@H](CC2=CC=C(OC)C(OC)=C2)[C@H]1CC3=CC=C(O)C(OC)=C3
Synonyms

(-)-Arctigenin
Structure Classification
- Phenylpropanoids
- Lignans
Initial Source
- Plants
- Compositae
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (17)

All WBCell Proliferation/Viability AssayCell Migration/Invasion AssayIn Vivo Efficacy StudyRT-PCR

Sort by:

Journal Impact Factor

Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May;155:104751. PMID: 32151678
Pharmacol Res

Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy. [Abstract]

2020 May;155:104721. PMID: 32097750

Arctigenin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 May;155:104721. [Abstract]

The Western blotting results show that incubating LA795 cells with 100 μM Arctigenin (24 h) led to a decrease in phospho-MEK1/2, phospho-ERK1/2 and cyclin D1 expression (n = 3).

Arctigenin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 May;155:104721. [Abstract]

Arctigenin (10-200 μM; 24 h) inhibited LA795 cell proliferation by inhibiting TMEM16A. (A), (B), (C) Inhibitory effect of arctigenin to the proliferation of LA795, HeLa and HEK293 cells with different concentrations (n = 8; ** means the P value was less than 0.01 compared with 0 μM group). (D) Inhibitory effect of NC shRNA, TMEM16A shRNA and shRNA added with 200 μM arctigenin to the proliferation of LA795 cells (n = 8; ** means the P value was less than 0.01 compared with control group).

Arctigenin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 May;155:104721. [Abstract]

Migration of LA795 cells in the presence of 0, 10, 20, 50, 100, and 200 μM Arctigenin assessed by wound healing assay.

Arctigenin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 May;155:104721. [Abstract]

The tumor volume growth curve in different groups (n = 6). Arctigenin (14.37 mg/kg; s.c.; once every two days for a total of 9 doses) inhibited the growth of lung adenocarcinomas in xenograft model mice.
J Pharm Anal

2026 Mar 10.
Life Sci

Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation. [Abstract]

2020 Sep 1;256:117983. PMID: 32565252

Arctigenin purchased from MedChemExpress. Usage Cited in: Life Sci. 2020 Sep 1;256:117983. [Abstract]

The indicated cell lines are treated with 5 μM Arc (Arctigenin) for 10 h and then harvested for extraction of total cellular RNA and subsequent qRT-PCR.
RSC Adv

A Natural product-based composite nanozyme synergistically induces ferroptosis for lung cancer therapy. [Abstract]

2026 May 26;16(31):28583-28591. PMID: 42211359
Eur J Pharmacol

A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. [Abstract]

2026 Mar 28:1019:178694. PMID: 41765270
Eur J Pharmacol

Arctigenin inhibits abnormal germinal center reactions and attenuates murine lupus by inhibiting IFN-I pathway. [Abstract]

2022 Mar 15:919:174808. PMID: 35151645
Mol Neurobiol

ARC-18 Alleviates Alzheimer-like Pathology and Cognitive Deficits via AdipoR1-Mediated Activation of Autophagy and Modulation of APP Processing. [Abstract]

2026 Feb 14;63(1):438. PMID: 41689616
Biomedicines

Arctigenin Attenuates Vascular Inflammation Induced by High Salt through TMEM16A/ESM1/VCAM-1 Pathway. [Abstract]

2022 Oct 31;10(11):2760. PMID: 36359280
Toxicol Appl Pharmacol

Arctigenin relieves inflammation and remodels the nasal epithelial barrier function in allergic rhinitis via the KLF5/BIRC3/NFκB axis. [Abstract]

2025 Aug 11:504:117510. PMID: 40803538
Chem Biol Drug Des

Preliminary Study on the Mechanism of Arctigenin in Alleviating Osteoarthritis Pain by Suppressing Chondrocyte Pyroptosis: The Potential Role of the POU2F1/GRB10 Axis. [Abstract]

2026 Apr;107(4):e70300. PMID: 42041039
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Biochem Biophys Res Commun

Non-cytotoxic nanomolar concentration of arctigenin protects neuronal cells from chemotherapy-induced ferroptosis by regulating SLC7A11-cystine-cysteine axis. [Abstract]

2024 May 28:710:149895. PMID: 38593620
Res Sq

2025 Aug 22.
SSRN

2025 Jul 8.
Heliyon

Arctigenin hinders the invasion and metastasis of cervical cancer cells via the FAK/paxillin pathway. [Abstract]

2023 May 25;9(6):e16683. PMID: 37292259
Research Square Preprint

2021 Aug.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (268.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6852 mL

13.4261 mL

26.8521 mL

5 mM

0.5370 mL

2.6852 mL

5.3704 mL

10 mM

0.2685 mL

1.3426 mL

2.6852 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Awale S, et, al. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 2006 Feb 1;66(3):1751-7. [Content Brief]

[2]. Gao Q, et, al. Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L. Acta Pharmacol Sin. 2018 May;39(5):787-801. [Content Brief]

[3]. Hayashi K, et, al. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. Biol Pharm Bull. 2010;33(7):1199-205. [Content Brief]

[4]. Wei L, et, al. Arctigenin Exerts Neuroprotective Effect by Ameliorating Cortical Activities in Experimental Autoimmune Encephalomyelitis In Vivo. Front Immunol. 2021 Jul 19;12:691590. [Content Brief]

[5]. Maxwell T, et, al. Arctigenin inhibits the activation of the mTOR pathway, resulting in autophagic cell death and decreased ER expression in ER-positive human breast cancer cells. Int J Oncol. 2018 Apr;52(4):1339-1349. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6852 mL	13.4261 mL	26.8521 mL	67.1303 mL
	5 mM	0.5370 mL	2.6852 mL	5.3704 mL	13.4261 mL
	10 mM	0.2685 mL	1.3426 mL	2.6852 mL	6.7130 mL
	15 mM	0.1790 mL	0.8951 mL	1.7901 mL	4.4754 mL
	20 mM	0.1343 mL	0.6713 mL	1.3426 mL	3.3565 mL
	25 mM	0.1074 mL	0.5370 mL	1.0741 mL	2.6852 mL
	30 mM	0.0895 mL	0.4475 mL	0.8951 mL	2.2377 mL
	40 mM	0.0671 mL	0.3357 mL	0.6713 mL	1.6783 mL
	50 mM	0.0537 mL	0.2685 mL	0.5370 mL	1.3426 mL
	60 mM	0.0448 mL	0.2238 mL	0.4475 mL	1.1188 mL
	80 mM	0.0336 mL	0.1678 mL	0.3357 mL	0.8391 mL
	100 mM	0.0269 mL	0.1343 mL	0.2685 mL	0.6713 mL

Keywords

Arctigenin

17 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Arctigenin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Anti-Aging Natural Product Library

Heterocyclic Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Arctigenin

Alle MMP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (17)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Arctigenin Related Classifications

HY-N0035 Related Classifications